Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
نویسندگان
چکیده
Whether the addition of rituximab to fludarabine and cyclosphosphamide (FC) increases early or late infection risk remains poorly defined. This retrospective analysis of 160 patients treated with FC+/-rituximab found no evidence of increased infection among patients receiving FC+rituximab, providing some evidence of safety for the continued exploration of this regimen.
منابع مشابه
The case for rituximab in AIDS-related lymphoma.
not show significant differences in early infection risk compared with those recorded in the preceding (non–rituximab-containing) regimens. Similarly, in randomized prospective comparisons of fludarabine versus F-R, 6 fludarabine, cyclophosphamide and mitoxantrone (FCM) versus FCM-rituximab, 7 and fludarabine, mitoxantrone, dexamethasone (FND) versus FND-rituximab, 8 no excess in early infectio...
متن کاملJanuszewicz David Westerman Treatment - related myelodysplasia following fludarabine combination chemotherapy
Myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) are well-recognized complications of therapy with alkylating agents and topoisomerase II inhibitors. A recent comprehensive review of reported MDS/sAML rates concluded that up to 10% of patients treated for non-Hodgkin’s lymphoma (NHL) using either conventional dose alkylator-based regimens or high-dose therapy develop MDS or sAML...
متن کاملBendamustine in the treatment of non-Hodgkin’s lymphomas
PURPOSE To review available data using bendamustine alone and in combination with other chemotherapeutic agents in treatment of patients with non-Hodgkin's lymphomas. METHODS Internet database searches and literature review. RESULTS Bendamustine was approved in March 2008 by the United States Food and Drug Administration for the treatment of patients with chronic lymphocytic leukemia. Many ...
متن کاملFludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy
Fludarabine-based regimens and CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens with or without rituximab are the most common treatment modalities for indolent lymphoma. However, there is no clear evidence to date about which chemotherapy regimen should be the proper initial treatment of indolent lymphoma. More recently, the use of fludarabine has raised concerns due ...
متن کاملEye Lymphoma: a Case Report
Non Hodgkin Lymphomas (NHL) are nodal or extra nodal monoclonal infiltrations by malignant lymphoid cells (B Lymphocytes in 80% of cases), which are distinguished as indolent or aggressive forms. According to the heterogeneity of lymphoid cells and their ubiquitous anatomical distribution, these disorders can develop in any organ and have very heterogeneous clinical expressions, but they are...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Haematologica
دوره 90 5 شماره
صفحات -
تاریخ انتشار 2005